WallStreetZenWallStreetZen

NASDAQ: HBIO
Harvard Bioscience Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Harvard Bioscience revenue was $94.14M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $24.6M, up 11.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, HBIO annual revenue was $94.1M, with -16.1% growth year-over-year.

HBIO past revenue growth

How has HBIO's revenue growth performed historically?

Company
-16.14%
Industry
9.74%
Market
20.68%
HBIO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
HBIO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
HBIO's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

HBIO revenue history

Current Revenue
$94.1M
Current Earnings
-$12.4M
Current Profit Margin
-13.2%

Be the first to know when HBIO announces revenue.

HBIO Revenue History By Year

HBIO Yearly RevenueHBIO RevenueHBIO ChangeHBIO Revenue Growth
2024-12-31$94.14M-$18.12M-16.14%
2023-12-31$112.25M-$1.09M-0.96%
2022-12-31$113.34M-$5.57M-4.68%
2021-12-31$118.90M$16.80M+16.46%
2020-12-31$102.10M-$14.08M-12.12%
2019-12-31$116.18M-$4.60M-3.81%
2018-12-31$120.77M$43.37M+56.02%
2017-12-31$77.41M-$27.11M-25.94%
2016-12-31$104.52M-$4.14M-3.81%
2015-12-31$108.66M$1.00k+0.00%
2014-12-31$108.66M$3.49M+3.32%
2013-12-31$105.17M-$6.00M-5.40%
2012-12-31$111.17M$2.31M+2.12%
2011-12-31$108.86M$685.00k+0.63%
2010-12-31$108.18M$22.41M+26.12%
2009-12-31$85.77M-$2.28M-2.59%
2008-12-31$88.05M$4.64M+5.57%
2007-12-31$83.41M$7.23M+9.49%
2006-12-31$76.18M$8.75M+12.98%
2005-12-31$67.43M$2.69M+4.15%
2004-12-31$64.75M$12.72M+24.45%
2003-12-31$52.02M-$5.36M-9.33%
2002-12-31$57.38M$16.51M+40.40%
2001-12-31$40.87M$10.29M+33.67%
2000-12-31$30.57M$4.40M+16.80%
1999-12-31$26.18M$14.02M+115.38%
1998-12-31$12.15M$689.87k+6.02%
1997-12-31$11.46MN/AN/A

1 of 2

Harvard Bioscience Revenue FAQ

What was HBIO's revenue last quarter?

On Invalid Date, Harvard Bioscience (NASDAQ: HBIO) reported Q4 2024 revenue of $24.56 million up 12.78% year over year. In the same quarter last year, Harvard Bioscience's revenue was $28.15 million.

What was Harvard Bioscience's revenue in 2024?

Harvard Bioscience's annual revenue for the twelve months ending Dec 31, 2024 was $94.14 million, a 16.14% decrease year over year.

How much does Harvard Bioscience make in a day?

Based on Harvard Bioscience annual revenue for the past five years, HBIO makes an average of $296,287.12 per day.

What was Harvard Bioscience's annual revenue growth in the past year?

As of Q2 2025, Harvard Bioscience's revenue has grown -16.14% year over year. This is 25.88 percentage points lower than the US Medical Instruments & Supplies industry revenue growth rate of 9.74%. Harvard Bioscience's revenue in the past year totaled $94.14 million.

How much does Harvard Bioscience make in a year?

Harvard Bioscience's revenue by year for the past five years is:
  • Harvard Bioscience's revenue for the twelve months ending Dec 31, 2024 was $94.14 million, a 16.14% decrease year over year.
  • Harvard Bioscience's annual revenue for Dec 31, 2023 was $112.25 million, a 0.96% decrease from 2022.
  • Harvard Bioscience's annual revenue for 2022 was $113.34 million, a 4.68% decrease from 2021.
  • Harvard Bioscience's annual revenue for 2021 was $118.90 million, a 16.46% increase from 2020.
  • Harvard Bioscience's annual revenue for 2020 was $102.10 million, a 12.12% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.